These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27183250)

  • 1. Idarucizumab for Dabigatran Reversal Guideline.
    Reardon DP; Owusu K
    Crit Pathw Cardiol; 2016 Jun; 15(2):33-5. PubMed ID: 27183250
    [No Abstract]   [Full Text] [Related]  

  • 2. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dabigatran specific antidote: new safety level in oral anticoagulation].
    MMW Fortschr Med; 2015 Nov; 157(19):78-9. PubMed ID: 26953416
    [No Abstract]   [Full Text] [Related]  

  • 4. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.
    Gendron N; Gay J; Lemoine M; Gaussem P; Lillo-Le-Louet A; Smadja DM
    Haematologica; 2018 May; 103(5):e226-e229. PubMed ID: 29472359
    [No Abstract]   [Full Text] [Related]  

  • 5. [Safer in everyday clinical care].
    Petersen PF; Grottke O
    MMW Fortschr Med; 2015 Nov; 157(19):79. PubMed ID: 26953417
    [No Abstract]   [Full Text] [Related]  

  • 6. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E
    Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
    Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
    Ting A; Venkat AR; Gawarikar Y; Patel R
    Med J Aust; 2019 Apr; 210(7):302-303.e1. PubMed ID: 30924530
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L; Gerstrøm G; Nybo M
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 15. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
    Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
    Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
    Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
    [No Abstract]   [Full Text] [Related]  

  • 19. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract]   [Full Text] [Related]  

  • 20. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.